.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,456,925

« Back to Dashboard

Claims for Patent: 5,456,925

Title: Pharmaceutical compositions containing furan derivatives
Abstract:The invention relates to a pharmaceutical composition in solid unit dosage form adapted for oral administration, comprising a salt formed between ranitidine and a complex of bismuth with a carboxylic acid selected from tartaric acid and citric acid together with an alkaline salt. For example the composition is in tablet form and comprises ranitidine bismuth citrate and sodium carbonate. The composition shows improved disintegration and/or dissolution.
Inventor(s): Smith; Norman R. (London, GB2), Heppenstall; Colin R. (Bishops Stortford, GB2), Douglas; Stephen J. (St. Albans, GB2)
Assignee: Glaxo Group Limited (Middlesex, GB)
Application Number:08/215,658
Patent Claims: 1. A pharmaceutical composition in tablet form which weighs from about 400 to about 900 mg, said composition comprising a salt formed between ranitidine and a complex of bismuth with a carboxylic acid selected from the group consisting of tartaric acid and citric acid, mixed with an effective amount of from 2 to 8% w/w of an alkaline salt, wherein the amount of alkaline salt is effective to increase the rate of disintegration and dissolution of said composition after swallowing by a patient, and wherein the alkaline salt is selected from the group consisting of carbonates, bicarbonates, citrates and acetates.

2. A composition according to claim 1, containing from 200 to 800 mg of ranitidine bismuth carboxylate per unit dose.

3. A composition according to claim 1, containing from 50 to 95% w/w of ranitidine bismuth carboxylate.

4. A composition according to claim 1, in which said salt of ranitidine is selected from the group consisting of: N-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2 -nitro-1, 1-ethenediamine 2-hydroxy-1,2,3-propanetricarboxylate bismuth (3.sup.+) complex; and N-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2 -nitro-1, 1-ethenediamine [R-(R*R*)]-2, 3-dihydroxybutanedioate bismuth (3.sup.+) complex.

5. A composition according to claim 1, in which said alkaline salt is selected from the group consisting of alkali metal and alkaline earth metal carbonates and bicarbonates and mixtures thereof.

6. A composition according to claim 1, in which said alkaline salt is selected from the group consisting of sodium carbonate, sodium bicarbonate and mixtures thereof.

7. A composition according to claim 1, in which said ranitidine bismuth carboxylateisN-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl ]-N'-methyl-2-nitro-1, 1-ethenediamine 2-hydroxy-1,2,3-propanetricarboxylate bismuth (3.sup.+) complex and said alkaline salt is sodium carbonate.

8. A composition according to claim 1, also containing one or more physiologically acceptable carriers or excipients.

9. A composition according to claim 1 in which said ranitidine bismuth carboxylateisN-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl ]-N'-methyl-2-nitro-1, 1-ethenediamine-2-hydroxy-1,2,3-propanetricarboxylate bismuth (3.sup.+) and said alkaline salt is sodium carbonate.

10. A composition according to claim 1 which contains about 5% by weight of the alkaline salt.

11. A composition according to claim 10 which contains about 400 mg of ranitidine bismuth citrate.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc